Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2001-07-05
2009-11-17
Parkin, Jeffrey S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S188100, C435S069100, C536S023720
Reexamination Certificate
active
07618642
ABSTRACT:
The present invention relates to polynucleotides encoding immunogenic HIV type C polypeptides. Uses of the polynucleotides in applications including DNA immunization, generation of packaging cell lines, and production of HIV Type C proteins are also described.
REFERENCES:
patent: WO 97/31115 (1997-08-01), None
patent: WO 99/41397 (1999-08-01), None
patent: WO 00/15819 (2000-03-01), None
patent: WO 03/004620 (2003-01-01), None
2008, Instructions to Authors, J. Virol. 82(1):1-19.
Johnson, P. R. , et al., 1992, Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: definition of minimum eptiopes and analysis of the effects of sequence variation, J. Exp. Med. 175:961-971.
Dai, L. C., et al., 1992, Mutation of human immunodeficiency virus type 1 at amino acid 585 on gp41 results in loss of killing by CD8+ A24-restricted cytotoxic T lymphocytes, J. Virol. 66(5):3151-3154.
Watkins, B. A., et al., Immune escape by human immunodeficiency virus type 1 from neutralizing antibodies: evidence for multiple pathways, J. Virol. 67(12):7493-7500.
Fenoglio, D., et al., 2000, Natural analogue peptides of HIV-1 gp120 T-helper epitope antagonize response of gp120-specific human CD4 T-cell clones, JAIDS 23:1-7.
McLain, L., et al., Different effects of a single amino acid substitution on three adjacent epitopes in the gp41 C-terminal tail of a neutralizing antibody escape mutant of human immunodeficiency virus type 1, Arch. Virol. 146:157-166.
Liu, Y., et al., 2006, Selection on the human immunodeficiency virus type 1 proteome following primary infection, J. Virol. 80(19):9519-9529.
Burton, D. R., and J. P. Moore, 1998, Why do we not have an HIV vaccine and how can we make one?, Nat. Med. Vacc. Suppl. 4(5):495-498.
Desrosiers, R. C., 2004, Prospects for an AIDS vaccine, Nat. Med. 10(3):221-223.
Pantaleo, G., and R. A. Koup, 2004, Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know, Nat. Med. 10(8):806-810.
Haas et al., “Cytotoxin T-Cell Responses to HIV-1 Reverse Transcriptase, Integrase and Protease,” AIDS, 12:1427-1436 (1998).
Hamajima, et al., “The Combination of DNA and Peptide Vaccines Induces Strong Immunities Against HIV-1 in Both Humoral and CMI,” 11THInternational AIDS Conference, Vancouver, Britich Columbia, Jul. 7-12; 11:6 (abstract No. Mo.A.151) (1996).
Kent, et al., “A Recombinant Avipoxvirus HIV-1 Vaccine Expressing Interferon-Gamma is Safe and Immunogenic in Macaques,” Vaccine 18:2250-2256 (2000).
Williamson, et al., “Designing HIV-1 Subtype C Vaccines for South Africa,” South African Journal of Science, 96:318-324 (2000).
Kolaskar et al., “A semi-empirical method for prediction of antigenic determinants on protein antigens.” FEBS Lett. (1990) 276:172-4.
Barnett et al., “The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region,” J Virol. Jun. 2001;75(12):5526-40.
Lee et al., “A single point mutation in HIV-1 V3 loop alters the immunogenic properties of rgp120,” Arch Virol. 2000;145(10):2087-103.
Chang et al., “Human immunodeficiency virus type 1 subtype E envelope recombinant peptides containing naturally immunogenic epitopes,” J Infect Dis. Aug. 2000;182(2):442-50.
Brusic et al., “Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network,”Bioinformatics14(2):121-30, 1998.
Carter, “Epitope Mapping of a Protein Using the Geysen (PEPSCAN) Procedure,”Methods Mol. Biol. 36:207-23, 1994.
Davenport et al., “An empirical method for th prediction of T-cell epitopes,”Immunogenetics42:392-97, 1995.
Feller & De La Cruz, “Identigying antigenic T-cell sites,”Nature349(6311):720-21, 1991.
Geysen et al., “Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid,”Proc. Natl. Acad. Sci. USA 81, 3998-4002, 1984.
Hopp, “Retrospective: 12 Years of Antigenic Determinant Predictions and More,”Peptide Research6:183-90, 1993.
Jameson et al., “The antigenic index: a novel algorithm for predicting antigenic determinants,”CABIOS4(1):1818-86, 1988.
Maksyutov & Zagrebelnaya, “ADEPT: a computer program for prediction of protein antigenic determinants,”Comput. Appl. Biosci. 9(3):291-97, 1993.
Meister et al., “Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes fromMycobacterium tuberculosisand HIV protein sequences,”Vaccine13(6):581-91, 1995.
Roberts et al., “Prediction of HIV Peptide Epitopes by a Noval Algorithm,”AIDS Res. Hum. Retroviruses12(7):593-610, 1996.
Welling et al., “Prediction of sequential antigenic regions in proteins,”FEBS Lett. 188:215-18, 1985.
Barnett Susan
Engelbrecht Susan
Lian Ying
Megede Jan zur
van Rensburg Estrelita Janse
Bautista Regina
Lee Helen
Novartis Vaccines and Diagnostics Inc.
Parkin Jeffrey S.
LandOfFree
Expression cassettes encoding modified human... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Expression cassettes encoding modified human..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Expression cassettes encoding modified human... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4070618